US$ 1.5B Deal, PTV News: Apr 01, 2010




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: US$ 1.5B Deal, PTV News: Apr 01, 2010
Released on: April 01, 2010. © PharmaVentures Ltd
Visitors: You are watching a 1 minute preview.
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
GSK and Isis to develop up to 6 drugs for rare and serious diseases
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Steven Renwick
Advisor
PharmaVentures

Steven is a transactions specialist with experience in asset divestments and IP screening and sourcing, as well as competitive analysis and licensing litigation cases wherein PharmaVentures served as expert witness. He also conducts research on industry licensing practices and has presented this work internationally. Previously, Steven managed PharmaVentures’ Strategic Intelligence division, with responsibility for the development and production of PharmaDeals®. Steven has a BSc (Hons) in Biochemistry from the University of Dundee and a PhD in Genetics from University College London.
PharmaVentures Ltd
PharmaVentures is a company that has proven success in deals and alliances.

PharmaVentures offers:


• Over 18 years of healthcare industry experience

• Experience gained from working with in excess of 1000 clients in 38 countries, and conducting more than 450 assignments

• Over 40 specialist advisors, analysts and researchers

• Skills honed in many countries - 80% of its business comes from outside the UK
GlaxoSmithKline (GSK)
GSK is the world's second largest pharmaceutical company, by employees; and a research-based company with a wide portfolio of pharmaceutical products covering anti-infectives, central nervous system, respiratory, gastro-intestinal/metabolic, oncology, and vaccines products. It also has a Consumer Healthcare operation comprising leading oral healthcare products, nutritional drinks, and over the counter medicines.
Isis Pharmaceuticals
The biotechnology company is developing drug therapies based on antisense technology, in which drugs attach themselves to strands of RNA in order to prevent them from producing disease-causing proteins; the hoped-for end result is a therapy that fights disease without harming healthy cells. Isis Pharmaceuticals works by discovering potential compounds (primarily in the areas of cardiovascular and metabolic disease but also in a range of other categories) and finding larger pharmaceutical partners to license the drugs or collaborate in their development.